Form PTO-1595 (modified)

1-3-92

1.

2.

RE

SHEET

U.S. Department of Commerce

Patent and Trademark Office

102366217 \_ \_ \_

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

2. Name and address of receiving party(ies):

Jorge Heller January 13, 2003 Steven Y. Ng January 13, 2003

1. Name of conveying party(ies), and execution date(s):

AP Pharma, Inc. 123 Saginaw Drive Redwood City CA 94063

Nature of conveyance:

ASSIGNMENT - copy (1 page)

4. Application number(s) or patent number(s):

Attorney Docket No. 10008-1197

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) App. No. 10/298,151

B. Patent No.(s)

5. Name and address of party to whom correspondence concerning document should be mailed:

> Heller Ehrman White & McAuliffe LLP 275 Middlefield Road Menlo Park CA 94025-3506

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41)..\$40.00

[X] Enclosed

[] Authorized to be charged to deposit account

8. Deposit Account Number:

08-1641

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Derek P. Freyberg, Reg. No. 29,250

Name of Person Signing

Total number of pages including cover sheet, attachments and document: [ 2 ]

SV 416644 v1 Prev SV 340185 02/06/03 5:46 PM

02/13/2003 LMUELLER 00000142 10298151

01 FC:8021

40.00 OP

**PATENT** REEL: 013748 FRAME: 0817 WHEREAS, we, Jorge Heller and Steven Y. Ng, are the original, first and joint inventors of certain subject matter entitled Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them (the "Invention"), for which we have filed US Patent Application No. 10/298,151, filed in the US PTO on November 15, 2002;

AND WHEREAS, A.P. Pharma, Inc., having an address at 123 Saginaw Drive, Redwood City CA 94063 ("A.P. Pharma"), a Delaware company, desires to perfect its right to the Invention and in the Letters Patent to be obtained therefor from the United States of America;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, we acknowledge A.P. Pharma's interest in the Invention and hereby assign to A.P. Pharma for the United States of America and all countries foreign thereto all our right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in the Invention, as described and claimed in Application No. 10/298,151, or in any continuation, division, reissue, reexamination or extension thereof and any legal equivalent thereof in a country foreign to the United States of America; the Invention, application and Letters Patent to be owned by A.P. Pharma, its successors, assigns and legal representatives, to the full end of the term for which such Letters Patent may be granted.

This assignment is effective as of the date of our signatures below.

I have read and understand this Assignment document for Application No. 10/298,151 and agree hereto, as indicated by my signature below.

INVENTOR	INVENTOR'S SIGNATURE	DATE
Jorge Heller	T. (lely	1/13/03
INVENTOR	INVENTOR'S SIGNATURE	DATE
Steven Y. Ng	5h 19	1/15/03

SV 409367 v1 12/30/02 11:20 AM (10008.1197)

> PATENT REEL: 013748 FRAME: 0818